Evidence map›Paper›PMID 42645349›Full record

ArticleCurrent oncology (Toronto, Ont.)2026

Shifting Cancer Landscapes in Korea: Divergent Incidence Trajectories, Sex-Specific Burdens, and Projected Case Counts for 24 Major Cancer Types from 1999 to 2023, with Forecasts to 2030.

Hyeran Jung, Minsun Jung

Abstract read
In one paragraph

Article in Current oncology (Toronto, Ont.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Hyeran JungDepartment of Pathology, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
Minsun JungDepartment of Pathology, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.ORCID 0000-0002-8701-4282

Funding

Ministry of Health and Welfare RS-2025-02223506
6 · The paper itself

Abstract

BACKGROUND/

objectivesKorea has experienced rapid and heterogeneous shifts in cancer epidemiology since 1999. We aimed to characterize divergent incidence trajectories across the 24 major cancer types, quantify sex-specific burdens, and project case counts through 2030.

methodsAnnual incidence data-including new case counts and age-standardized incidence rates (ASIRs) per 100,000 (2020 Korean standard population) stratified by sex-were extracted from the KCCR via the Korean Statistical Information Service (KOSIS) for 1999-2023. Annual percent change (APC) was estimated by log-linear regression with 95% confidence intervals (CIs). Holt-Winters damped exponential smoothing generated 2024-2030 projections with 95% prediction intervals (PIs). Changes in case ascertainment and coding over the study period were considered in interpretation.

resultsTotal incidence increased from 101,854 (1999) to 288,613 cases (2023), a 183.4% increase. Overall ASIR rose from 402.7 to 522.9 per 100,000. Of the 24 cancer types, 15 showed statistically significant increasing ASIR trends, 6 showed significant decreasing trends, and 3 showed no significant change. The highest-APC cancers were thyroid (+7.56%), prostate (+6.98%), testis (+5.39%), breast (+5.03%), and corpus uteri (+5.03%; all

conclusionsKorean cancer epidemiology is undergoing a pronounced transition from infection-related toward metabolic, hormonal, and aging-related malignancies, with a marked and widening sex-specific divergence. Cancer-type-resolved projections through 2030 provide an evidence base for strategic capacity planning in Korean oncology.

Indexed as

NeoplasmsAdultFemaleForecastingHumansIncidenceMaleMiddle AgedRepublic of KoreaSex Factorsage distributionepidemiologic studiesforecastingincidenceneoplasmspopulation surveillanceregistriesRepublic of Koreasex distribution

Identifiers

PMID42645349
PMCPMC13510937

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.